NEW YORK – On the second day of the 39th annual JP Morgan Healthcare Conference, Eli Lilly and Pfizer discussed the potential of their competing CDK4/6 inhibitors; GSK highlighted a trial comparing bintrafusp alfa against pembrolizumab (Merck’s Keytruda) in PD-L1-high, advanced non-small cell lung cancer; and Clovis Oncology detailed plans to expand its PARP inhibitor rucaparib (Rubraca) into new biomarker-guided indications. Below are brief reports on the presentations covered by our team.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.